Home / Health / Respiratory Illness Soars: Drug Sales Spike Over ₹1700 Cr
Respiratory Illness Soars: Drug Sales Spike Over ₹1700 Cr
11 Feb
Summary
- Respiratory medicine sales increased by over ₹1700 crore from 2024 to 2025.
- Government cites air pollution as a major trigger for respiratory illnesses.
- Experts urge stronger air quality controls and preventive health measures.
Sales of medicines treating respiratory ailments saw a substantial increase from 2024 to 2025. Data from the NPPA indicates a rise of over ₹1700 crore in the total sales value of respiratory system medicines in December alone. This surge reflects a growing demand for drugs addressing conditions like asthma, COPD, and allergies.
The government has identified air pollution as a primary trigger for respiratory illnesses. While acknowledging the lack of conclusive data directly linking air pollution solely to deaths or diseases, it recognizes it as a significant contributing factor. Health experts highlight that a combination of factors, including lifestyle and environmental influences, synergistically impacts respiratory health.
Public health experts interpret the sales data as evidence of mounting pressure on the nation's respiratory health. They advocate for enhanced air quality controls and long-term preventive measures to mitigate the root causes of these illnesses. Experts like Dr. Randeep Guleria and Dr. Akshay Budhraja stress the harmful impact of air pollutants, citing epidemiological and lab data that link them to increased mortality and the worsening of chronic respiratory conditions.
